Chinese expert consensus on antiviral therapy for hepatitis B virus-related hepatocellular carcinoma (2023 edition)

The incidence of hepatocellular carcinoma (hereafter referred to as "HCC") in China is high, especially the proportion of hepatitis B virus-related HCC. Along with anti-tumor treatment, antiviral therapy has become an important part of the comprehensive treatment of hepatitis B virus-related HCC, running through the whole process and covering the full stage of HCC treatment. In recent years, domestic and international scholars have conducted plenty of studies on the effect of viral factors on the development of HCC and how antiviral therapy improving the prognosis of HCC patients. Results of relevant studies have been widely recognized in the clinic, which playing essential roles in prolonging the survival of HCC patients. The Chinese expert consensus on antiviral therapy for hepatitis B virus-related hepatocellular carcinoma (2023 edition) integrates the experience of antiviral therapy in China and the latest domestic and international studies, aiming to seek common ground while reserving differences based on this original version, and apply antiviral therapy more scientifically and effectively in the comprehensive treatment of HCC.